Portal de Periódicos da CAPES

Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain

2022; Lippincott Williams & Wilkins; Volume: 47; Issue: 7 Linguagem: Inglês

10.1097/rlu.0000000000004162

1536-0229

Alyaa Sadeq, Sharjeel Usmani, Abdulredha Esmail, Wael Fathallah, Mahmoud Alfeeli, Fahad Marafi,

Brain Metastases and Treatment

18F-PSMA PET/CT is an emerging standard of care in staging prostate cancer, evaluating biochemical recurrence and response to therapy. Despite the nomenclature, PSMA expression is also documented at the tumor-associated neovasculature of other malignant solid tumors including renal cell carcinoma. We report a case of 44-year-old man known to have renal cell carcinoma who underwent 18F-PSMA and 18F-FDG PET/CT for restaging after radical nephrectomy. A well-defined solitary cerebellar lesion with marked PSMA expression and equivocal FDG uptake was noted. MRI brain confirmed a matching cerebellar metastatic lesion. 18F-PSMA expression in the metastatic RCC raises a prospective guide to futuristic theragnostic uses.